Show simple item record

dc.contributor.authorBenatti, Hector Ribeiro
dc.contributor.authorGray-Edwards, Heather L
dc.date.accessioned2023-01-24T13:41:00Z
dc.date.available2023-01-24T13:41:00Z
dc.date.issued2022-01-17
dc.identifier.citationBenatti HR, Gray-Edwards HL. Adeno-Associated Virus Delivery Limitations for Neurological Indications. Hum Gene Ther. 2022 Jan;33(1-2):1-7. doi: 10.1089/hum.2022.29196.hrb. PMID: 35049369.en_US
dc.identifier.eissn1557-7422
dc.identifier.doi10.1089/hum.2022.29196.hrben_US
dc.identifier.pmid35049369
dc.identifier.urihttp://hdl.handle.net/20.500.14038/51576
dc.description.abstractIn this commentary we discuss pitfalls and limitations of current adeno-associated virus (AAV) delivery routes, dose scaling, and the extrapolation of animal data to first-in-human (FIH) AAV clinical trials.en_US
dc.language.isoenen_US
dc.relation.ispartofHuman Gene Therapyen_US
dc.relation.urlhttps://doi.org/10.1089/hum.2022.29196.hrben_US
dc.titleAdeno-Associated Virus Delivery Limitations for Neurological Indicationsen_US
dc.typeEditorialen_US
dc.source.journaltitleHuman gene therapy
dc.source.volume33
dc.source.issue1-2
dc.source.beginpage1
dc.source.endpage7
dc.source.countryUnited States
dc.identifier.journalHuman gene therapy
dc.contributor.departmentHorae Gene Therapy Centeren_US
dc.contributor.departmentRadiologyen_US


This item appears in the following Collection(s)

Show simple item record